190 related articles for article (PubMed ID: 25334045)
1. Amotosalen-HCl-UVA pathogen reduction does not alter poststorage metabolism of soluble CD40 ligand, Ox40 ligand and interkeukin-27, the cytokines that generally associate with serious adverse events.
Hamzeh-Cognasse H; Laradi S; Osselaer JC; Cognasse F; Garraud O
Vox Sang; 2015 Feb; 108(2):205-7. PubMed ID: 25334045
[TBL] [Abstract][Full Text] [Related]
2. Prevention of transfusion-associated graft-versus-host disease with pathogen-reduced platelets with amotosalen and ultraviolet A light: a review.
Cid J
Vox Sang; 2017 Oct; 112(7):607-613. PubMed ID: 28833219
[TBL] [Abstract][Full Text] [Related]
3. Immune-reactive soluble OX40 ligand, soluble CD40 ligand, and interleukin-27 are simultaneously oversecreted in platelet components associated with acute transfusion reactions.
Hamzeh-Cognasse H; Damien P; Nguyen KA; Arthaud CA; Eyraud MA; Chavarin P; Absi L; Osselaer JC; Pozzetto B; Cognasse F; Garraud O
Transfusion; 2014 Mar; 54(3):613-25. PubMed ID: 23944651
[TBL] [Abstract][Full Text] [Related]
4. A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment.
Knutson F; Osselaer J; Pierelli L; Lozano M; Cid J; Tardivel R; Garraud O; Hervig T; Domanovic D; Cukjati M; Gudmundson S; Hjalmarsdottir IB; Castrillo A; Gonzalez R; Brihante D; Santos M; Schlenke P; Elliott A; Lin JS; Tappe D; Stassinopoulos A; Green J; Corash L
Vox Sang; 2015 Nov; 109(4):343-52. PubMed ID: 25981525
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of amotosalen-ultraviolet A pathogen-inactivated platelets stored for up to 7 days.
Infanti L; Holbro A; Passweg J; Bolliger D; Tsakiris DA; Merki R; Plattner A; Tappe D; Irsch J; Lin JS; Corash L; Benjamin RJ; Buser A
Transfusion; 2019 Nov; 59(11):3350-3361. PubMed ID: 31574181
[TBL] [Abstract][Full Text] [Related]
6. Pathogen inactivation of double-dose buffy-coat platelet concentrates photochemically treated with amotosalen and UVA light: preservation of in vitro function.
Sandgren P; Diedrich B
Vox Sang; 2015 May; 108(4):340-9. PubMed ID: 25557354
[TBL] [Abstract][Full Text] [Related]
7. Profiling alterations in platelets induced by Amotosalen/UVA pathogen reduction and gamma irradiation--a LC-ESI-MS/MS-based proteomics approach.
Thiele T; Sablewski A; Iuga C; Bakchoul T; Bente A; Görg S; Völker U; Greinacher A; Steil L
Blood Transfus; 2012 May; 10 Suppl 2(Suppl 2):s63-70. PubMed ID: 22890270
[TBL] [Abstract][Full Text] [Related]
8. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates.
Kaiser-Guignard J; Canellini G; Lion N; Abonnenc M; Osselaer JC; Tissot JD
Blood Rev; 2014 Nov; 28(6):235-41. PubMed ID: 25192602
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light.
Lanteri MC; Santa-Maria F; Laughhunn A; Girard YA; Picard-Maureau M; Payrat JM; Irsch J; Stassinopoulos A; Bringmann P
Transfusion; 2020 Jun; 60(6):1319-1331. PubMed ID: 32333396
[TBL] [Abstract][Full Text] [Related]
10. Patient outcomes and amotosalen/UVA-treated platelet utilization in massively transfused patients.
Nussbaumer W; Amato M; Schennach H; Astl M; Chen CY; Lin JS; Corash L; Benjamin RJ
Vox Sang; 2017 Apr; 112(3):249-256. PubMed ID: 28198023
[TBL] [Abstract][Full Text] [Related]
11. Pathogen inactivation with amotosalen plus UVA illumination minimally impacts microRNA expression in platelets during storage under standard blood banking conditions.
Arnason NA; Johannson F; Landrö R; Hardarsson B; Irsch J; Gudmundsson S; Rolfsson O; Sigurjonsson OE
Transfusion; 2019 Dec; 59(12):3727-3735. PubMed ID: 31674051
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of yellow fever virus with amotosalen and ultraviolet A light pathogen-reduction technology.
Girard YA; Santa Maria F; Lanteri MC
Transfusion; 2020 Mar; 60(3):622-627. PubMed ID: 31957887
[TBL] [Abstract][Full Text] [Related]
13. Biochemical and functional characteristics of stored (double-dose) buffy-coat platelet concentrates treated with amotosalen and a prototype UVA light-emitting diode illuminator.
Brouard N; Pissenem-Rudwill F; Mouriaux C; Haas D; Galvanin A; Kientz D; Mangin PH; Isola H; Hechler B
Transfusion; 2023 Oct; 63(10):1937-1950. PubMed ID: 37615493
[TBL] [Abstract][Full Text] [Related]
14. Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian Regional Medical Centre.
Amato M; Schennach H; Astl M; Chen CY; Lin JS; Benjamin RJ; Nussbaumer W
Vox Sang; 2017 Jan; 112(1):47-55. PubMed ID: 28001297
[TBL] [Abstract][Full Text] [Related]
15. Platelet components associated with adverse reactions: predictive value of mitochondrial DNA relative to biological response modifiers.
Cognasse F; Aloui C; Anh Nguyen K; Hamzeh-Cognasse H; Fagan J; Arthaud CA; Eyraud MA; Sebban M; Fromont E; Pozzetto B; Laradi S; Garraud O
Transfusion; 2016 Feb; 56(2):497-504. PubMed ID: 26446055
[TBL] [Abstract][Full Text] [Related]
16. Riboflavin and amotosalen photochemical treatments of platelet concentrates reduce thrombus formation kinetics in vitro.
Van Aelst B; Feys HB; Devloo R; Vanhoorelbeke K; Vandekerckhove P; Compernolle V
Vox Sang; 2015 May; 108(4):328-39. PubMed ID: 25557250
[TBL] [Abstract][Full Text] [Related]
17. [Photochemical inactivation of pathogens in platelets and plasma: five years of clinical use in routine and hemovigilance. Towards a change of paradigm in transfusion safety].
Cazenave JP
Transfus Clin Biol; 2011 Apr; 18(2):53-61. PubMed ID: 21474358
[TBL] [Abstract][Full Text] [Related]
18. Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance.
Stivala S; Gobbato S; Infanti L; Reiner MF; Bonetti N; Meyer SC; Camici GG; Lüscher TF; Buser A; Beer JH
Haematologica; 2017 Oct; 102(10):1650-1660. PubMed ID: 28729303
[TBL] [Abstract][Full Text] [Related]
19. Pathogen reduction treatment of buffy coat platelet concentrates in additive solution induces proapoptotic signaling.
Reid S; Johnson L; Woodland N; Marks DC
Transfusion; 2012 Oct; 52(10):2094-103. PubMed ID: 22320126
[TBL] [Abstract][Full Text] [Related]
20. Pathogen reduction with amotosalen/UVA reduces platelet refractoriness in a dog platelet transfusion model.
Slichter SJ; Bailey SL; Gettinger I; Pellham E; Christoffel T; Castro G; Green JM; Stassinopoulos A
Vox Sang; 2019 Aug; 114(6):595-604. PubMed ID: 31297836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
